Join the Amyotrophic Lateral Sclerosis group to help and get support from people like you.
Amyotrophic Lateral Sclerosis News (Page 2)
Related terms: ALS (amyotrophic lateral sclerosis), Amyotrophic Lateral Sclerosis (ALS), Lou Gehrig's Disease, Motor Neurone Disease, ALS
Elon Musk's Neuralink Says Brain-to-Computer Interface Has FDA Approval for Clinical Trial
FRIDAY, May 26, 2023 – It may sound like the stuff of science fiction, but Elon Musk’s company Neuralink announced Thursday that the U.S. Food and Drug Administration has approved a human clinical t...
Allopurinol May Cut Risk for Neurodegenerative Diseases
FRIDAY, May 19, 2023 – Xanthine dehydrogenase/oxidase blockers may reduce the risk for neurodegenerative diseases, according to a study published online May 17 in PLOS ONE. Yizhe Song, from the...
FDA Grants Accelerated Approval for Qalsody (tofersen) for the Treatment of Amyotrophic Lateral Sclerosis Associated with a Mutation in the SOD1 Gene
CAMBRIDGE, Mass., April 25, 2023 (GLOBE NEWSWIRE) – Biogen Inc. (Nasdaq: BIIB) announced today that the U.S. Food and Drug Administration (FDA) has approved Qalsody (tofersen) 100 mg/15mL injection...
FDA Approves Relyvrio (sodium phenylbutyrate/taurursodiol) for Patients with Amyotrophic Lateral Sclerosis (ALS)
Relyvrio (previously known as AMX0035 in the U.S.) is an oral, fixed-dose combination therapy for the treatment of adults with ALS Relyvrio significantly slowed loss of physical function in a...
FDA Approves Radicava ORS (edaravone) for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
JERSEY CITY, N.J., May 13, 2022 /PRNewswire/ – Mitsubishi Tanabe Pharma Corporation (MTPA) today announced the U.S. Food and Drug Administration (FDA) has approved Radicava ORS (edaravone), the o...
FDA Approves Exservan (riluzole) Oral Film for the Treatment of Amyotrophic Lateral Sclerosis
WARREN, N.J., Nov. 25, 2019 (GLOBE NEWSWIRE) – Aquestive Therapeutics, Inc. (NASDAQ: AQST), a specialty pharmaceutical company focused on developing and commercializing differentiated products to...
ITF Pharma Announces FDA Approval of Tiglutik (riluzole) Oral Suspension for the Treatment of Amyotrophic Lateral Sclerosis (ALS)
BERWYN, Pa., Sept. 6, 2018 /PRNewswire/ – ITF Pharma, a U.S.-based specialty pharmaceutical company and a subsidiary of Italfarmaco, a privately-held European specialty pharmaceutical company,...
FDA Approves Radicava (edaravone) to Treat Amyotrophic Lateral Sclerosis (ALS)
May 5, 2017 – The U.S. Food and Drug Administration today approved Radicava (edaravone) to treat patients with amyotrophic lateral sclerosis (ALS), commonly referred to as Lou Gehrig’s disease. “...
Ask a question
To post your own question to this support group, sign in or create an account.